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Abstract
The transcription factor interferon regulatory factor-8 (IRF-8) is crucial for myeloid cell development and immune
response and also acts as a tumor suppressor gene. Here, we analyzed the role of IRF-8 in the cross talk between
melanoma cells and tumor-infiltrating leukocytes. B16-F10melanoma cells transplanted into IRF-8–deficient (IRF-8−/−)
mice growmore rapidly, leading to higher numbers of lung metastasis, with respect to control animals. These events
correlated with reduced dendritic cell and T cell infiltration, accumulation of myeloid-derived suppressor cells and
a chemokine/chemokine receptor expression profile within the tumor microenvironment supporting tumor growth,
angiogenesis, and metastasis. Noticeably, primary tumors developing in IRF-8−/−mice displayed a clear-cut inhibition
of IRF-8 expression in melanoma cells. Injection of the demethylating agent 5-aza-2′-deoxycytidine into melanoma-
bearing IRF-8−/− animals induced intratumoral IRF-8 expression and resulted in the re-establishment of a chemokine/
chemokine receptor pattern favoring leukocyte infiltration and melanoma growth arrest. Importantly, intrinsic IRF-8 -
expression was progressively down-modulated during melanoma growth in mice and in humanmetastatic melanoma
cells with respect to primary tumors. Lastly, IRF-8 expression in melanoma cells was directly modulated by soluble
factors, among which interleukin-27 (IL-27), released by immune cells from tumor-bearing mice. Collectively, these
results underscore a key role of IRF-8 in the cross talk between melanoma and immune cells, thus revealing its critical
function within the tumor microenvironment in regulating melanoma progression and invasiveness.
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Introduction
Cancer progression and invasiveness are complex multistep phenomena
involving continuous interactions between host and cancer cells, prefer-
entially occurring within the tumor microenvironment [1]. Melanoma
is a very aggressive tumor with a high metastatic potential, known to
be highly resistant to conventional chemotherapy, immunotherapy,
and targeted therapy [2]. Melanoma cells can secrete immunomodu-
latory factors that edit an intratumoral milieu that suppresses immuno-
surveillance mechanisms, thus enabling tumor progression [3]. During
melanoma carcinogenesis, the activity of immune infiltrates, such as
dendritic cells (DCs) and CD4+ and CD8+ T lymphocytes, is crucially
affected by the prevalence of immunosuppressive signals within
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the tumor microenvironment and by the accumulation of suppressive
immune populations, such as myeloid-derived suppressor cells
(MDSCs) or regulatory T cells (Tregs) [4]. However, melanoma cells
secrete a number of chemokines that promote tumor angiogenesis [5].
In the recent past, chemokines have also emerged as major determi-
nants of melanoma metastasis [6]. Although it is generally accepted that
local interactions between resident and infiltrating cells play a key role
in melanoma development, the fine mechanisms generating the contin-
uous alterations of the tumor microenvironment sustaining cancer
progression need to be further elucidated.
The transcription factor interferon regulatory factor-8 (IRF-8), a
member of the IRF family, plays a dual role in antitumor response by
modulating, on the one hand, immune responses and, on the other
hand, cell growth and differentiation of various tumor cells [7]. IRF-8
expression governs myeloid cell developmental program, and mice
deficient for this factor (IRF-8−/−) display substantial defects in mono-
cyte and DC differentiation and activity, being devoid of plasmacytoid
DCs (pDCs) and exhibiting functional alterations of CD8α+ and
CD8α− DCs [8–10]. Noteworthy, IRF-8 plays a direct role in tumor
development, as it confers resistance to apoptosis in myeloid pop-
ulations and its deficiency supports the development of a chronic mye-
logenous leukemia (CML)–like syndrome in mice [11,12]. Of interest,
the role of IRF-8 in solid tumor cell biology has also emerged [7,13].
Loss of IRF-8 has been frequently detected in a large collection of pri-
mary carcinomas and the suppression of its function has been correlated
to enhanced metastatic potential of sarcoma cells [14,15]. These find-
ings have defined IRF-8 as a tumor suppressor gene, although the exact
mechanisms by which it operates as well as its role in melanoma biology
remain elusive. By using IRF-8−/− mice transplanted with B16-F10
melanoma cells, we here report a previously unrecognized role of
IRF-8 in regulating melanoma progression and metastatic process
through the active control of cancer and immune cell cross talk within
the tumor microenvironment.
Materials and Methods
Cell Lines
B16-F10murinemelanoma cell line and the human cell line Colo-38
were purchased, respectively, from American Type Culture Collection-
LGC (ATCC-LGC, Milan, Italy; CRL-6475) and Cell Lines Service
(CLS, Eppelheim, Germany; 300151). The cell line M-14 was part
of the NC160 cell lines and was obtained from Dr Susan Holbeck
(National Cancer Institute). The cell lines Alo-39, PES-41, PES-43,
and PES-47 were generated from metastatic melanoma lesions by
Dr Lombardi in the Laboratory of Immunology, “G. Pascale Founda-
tion” (Naples, Italy) [16]. Ovalbumin (OVA)–expressing B16melanoma
cells (B16.OVA) were kindly provided by Dr Laurence Zitvogel (Institut
Gustave Roussy, Villejuif, France). Parental B16-F0 melanoma cells
were a generous gift from Dr Elena Pagani (Istituto Dermopatico
dell’Immacolata, Rome, Italy). The cells were routinely tested for
morphology, growth curve, and absence of mycoplasma and passaged
for no more than three times from thawing.
Mice and In Vivo Treatments
IRF-8−/− were generated as described [11] and backcrossed on a
C57BL/6 background. C57BL/6 IRF-8−/− and wild-type (WT) mice
were housed in the animal facility at the Istituto Superiore di Sanità
(Rome, Italy) and manipulated in accordance with the local Ethical
Committee guidelines. B16-F10 or B16.OVA melanoma cells
were injected subcutaneously (s.c.; 0.8 × 106). Where indicated, mice
were injected intraperitoneally (i.p.) with 250 μg/kg of 5-aza-2′-
deoxycytidine (5-Aza-dC; Sigma, St Louis, MO) dissolved in 200 μl of
phosphate-buffered saline (PBS). The control group consisted of mice
injected with 200 μl of PBS. For induction of experimental pulmonary
metastasis, mice were injected intravenously with 1.5 × 106 B16-F10 cells
and sacrificed 5 days later for counts of metastatic foci in lungs.
Histologic Analysis
Tumors were excised with scissors and the inner part of the lesions
was taken. Explanted melanoma tissues were fixed with 4% para-
formaldehyde for 24 hours, then embedded in paraffin, sectioned at
5-μm thickness, and stained with hematoxylin and eosin (H&E).
Analysis of Immune Cell Infiltrate in Melanoma
For fluorescence-activated cell sorting (FACS) analysis, melanoma
explants were cut into small fragments using curved scissors and then
digested in type III collagenase–containing medium (1 mg/ml;
Worthington Biochemicals, Lakewood, NJ) for 30minutes at room tem-
perature in agitation, followed by EDTA (0.1 M, pH 7.2) for additional
5 minutes. The homogenate was then passed through a cell strainer and
the resulting cell suspension was treated with lysis buffer (140 mM
NH4Cl, 17 mM Tris HCl, pH 7.2) to eliminate red blood cells. Cells
were then stained with peridinin-chlorophyll-protein complex (PerCP)
anti-CD45, allophycocyanin anti-CD11c, fluorescein isothiocyanate
(FITC) anti-CD8a, PerCP or biotin anti-CD4, phycoerythrin (PE)
anti-CD357/GITR, PE anti–CD124/interleukin-4 (IL-4R), FITC
anti-Foxp3, biotin anti-CD45R/B220, biotin anti-CD40, biotin anti-
CD80, biotin anti-CD86, biotin anti–I-A/I-E (all from BD Pharmingen,
San Diego, CA), allophycocyanin anti-CD25, allophycocyanin anti–
Gr-1, and FITC anti-CD11b (Miltenyi Biotec, Bergisch Gladbach,
Germany). Biotinylated antibodies were detected by streptavidin PE
(BD Pharmingen). The CD45 labeling allowed discriminating between
leukocytes (CD45+ cells) and tumor tissue cells, composed of stromal
cells and B16melanoma cells. T lymphocytes were detected as CD4+ or
CD8+ CD45+CD11c−. Total tumor-infiltrating DCs were defined as
CD45+CD11c+I-A+, plasmacytoid DCs as CD45+CD11lowB220+
CD11b−, MDSCs as CD45+CD11b+Gr-1+CD124/IL-4R+, and Tregs
as CD4+CD25+CD357/GITR+Foxp3+. For confocal laser scanning
microscopy (CLSM) analysis, melanoma tissues grown in WT and
IRF-8−/−mice were snap-frozen, embedded in optimal cutting tempera-
ture compound (Tissue-Tek), and stored at −80°C. Frozen tumor sections
(5 μm tick) were then obtained and fixed in cold acetone. Sections were
stained with FITC anti-CD11c antibody combined with biotin anti–
I-Ad/I-Ed for detection of DCs or with biotin anti-mPDCA1 (Miltenyi
Biotec) for detection of pDCs. T lymphocytes were detected by labeling
with biotin anti-CD3 antibody in combination with FITC-conjugated
anti-CD4 or anti-CD8. Biotin-conjugated monoclonal antibodies were
detected with streptavidin–Alexa Fluor 594 (Invitrogen, Carlsbad, CA).
Nuclei were visualized with 4′,6-diaminidino-2-phenylindole (DAPI)
(1 μg/ml). CLSM observations were performed with a Leica TCS
SP2 AOBS apparatus, using 405-, 488-, 594-nm excitation spectral
laser lines appropriately tuned by acousto-optical tunable filter. Signals
from different fluorescent probes were taken in sequential scan settings,
and co-localization was detected in yellow.
Proliferation Assays
Tumor-infiltrating leukocytes from B16.OVA-bearing mice were
isolated bymagnetic cell sorting using anti-CD45microbeads (Miltenyi
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Biotec). CD45+ cells (>80% pure; 3 × 105) and spleen cells (3 × 106)
from B16.OVA-bearing mice were seeded in 96-well round-bottomed
plates in the presence or absence of graded amounts ofOVAprotein or of
major histocompatibility complex (MHC) class I–restricted SIINFEKEL
peptide of OVA (1 μM). Cell cultures were incubated in complete
medium for 3 days at 37°C in 5%CO2 and then pulsedwith
3H-thymidine
(1 μCi/well) for 16 hours. Incorporation of 3H-thymidine was analyzed
by liquid scintillation counting.
Methylation-specific Polymerase Chain Reaction
GenomicDNAwas purified from tumor cells by using the salting out
method [17]. Sodium bisulfite treatment of genomic DNA to convert
unmethylated cytosine to thymidine was carried out using CpGenome
Universal DNAModification Kit (Chemicon, Temecula, CA) according
to the manufacturer’s instructions. Methylation-sensitive polymerase
chain reaction (PCR) primers were designed by using the Methyl Primer
Express software. The PCR sequences, targeting a CpG island within the
IRF-8 promoter region (Figure W1), are the following: unmethylated
forward primer, 5′-AGGATTATTGAGTTTGAAAGAGTG-3′;
unmethylated reverse primer, 5′-TTTTCCTACTACTATCACAT-
AAAAA-3′; methylated forward primer, 5′-ATTATCGAGTTTGAAA-
GAGCG-3′; methylated reverse primer 5′-TCCTACTACTAT-
CGCGTAAAAA-3′. These primers amplify a 179-bp sequence inside
the mentioned CpG island.
Quantitative Reverse Transcription–PCR
Total RNA was extracted from tumor tissue by using TRIzol
reagent (Invitrogen). Messenger RNA was reverse transcribed by
means of Verso cDNA Kit (Thermo Scientific, Waltham, MA).
Quantitative reverse transcription–PCR (qRT-PCR) was performed
using Sensimix Plus SYBR Kit containing the fluorescent dye SYBR
Green (Quantace, Watford, United Kingdom). Forward and reverse
primers (Table W1) were purchased from Primm (Milan, Italy). The
conditions of real-time PCR reaction were given as follows: 15 seconds
at 95°C, 30 seconds at 60°C, and 45 seconds at 72°C (45 cycles). PCR
products were continuously measured by means of an ABI 7500 Real-
Time PCR System (Applied Biosystems, Carlsbad, CA). Quality and
specificity of amplicons in each sample was detected by dissociation
curve analysis. Triplicates were performed for each experimental point.
For quantization, threshold cycle (CT) values were determined by the
Sequence Detection System software (Applied Biosystems), and ΔCT
was obtained by subtracting CT of reference gene, β-actin, to CT of
target gene. Gene expression was presented as relative amount of
mRNA normalized to β-actin and was calculated as 2−ΔCt, a modifi-
cation of the 2−ΔΔCt method [18].
Protein Extraction and Western Blot Analysis
Proteins were extracted from melanoma bulks at different tumor
progression stages or from B16-F10 cells, untreated or treated with
interferon-γ (IFN-γ, 100 ng/ml) as positive control. In addition, pro-
teins were also purified from melanoma lesions grown in IRF-8−/−
mice treated with PBS or 5-Aza-dC. Briefly, 10 × 106 tumor cells were
incubated for 30 minutes on ice in lysis buffer [50 mM Tris HCl (pH
8.0), 120 mM NaCl, 0.25% NP-40, 0.1% sodium dodecyl sulfate;
Sigma] containing the protease inhibitors PMSF, aprotinin, leupeptin,
and pepstatin (Roche, Mannheim, Germany), each at a final concen-
tration of 10 ng/ml, and 1 mM DTT (Sigma). A quantity of 30 μg of
each protein sample was loaded onto a 10% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis gel. Following separation, proteins
were blotted onto a nitrocellulose membrane (Whatman). Membranes
were blocked with 5% nonfat dry milk in PBS–0.5% Tween 20 and
then probed with rabbit anti-mouse IRF-8 polyclonal antibody (Santa
Cruz Biotechnology, Santa Cruz, CA) or anti-mouse β-tubulin mono-
clonal antibody (Sigma), followed by HRP-conjugated anti-rabbit IgG
antibody or anti-mouse IgG antibody (Amersham Pharmacia Biotech,
Uppsala, Sweden). Immunoreactive protein bands were detected by
using the ECL Detection Kit (Amersham Pharmacia Biotech).
Cytokines
Recombinant murine IL-3, IL-6, IL-10 (ProSpec, East Brunswick,
NJ), and interleukin-27 (IL-27; Cell Signaling Technology, Beverly,
MA) were used at 50 ng/ml.
Transwell Co-cultures of B16-F10 Melanoma/Immune Cells
Spleen cells (2 × 106) from naïve or melanoma-bearing WT and
IRF-8−/− mice, at 19 days after tumor implant, were plated on the
upper compartment of 0.4-μm pore size transwell plates (Costar)
in 0.1 ml of RPMI complete medium. B16-F10 melanoma cells
(0.3 × 106 in 0.6 ml) were placed on the lower chamber. Co-cultures
were incubated for 24 hours at 37°C and 5%CO2, after which B16 cells
were harvested and total RNA was extracted. Samples were then assayed
for IRF-8 expression by qRT-PCR. Supernatants from co-cultures
were harvested and tested for cytokine release using RayBio mouse
cytokine antibody array membranes (Raybiotech, Norcross, GA) fol-
lowing the manufacturer’s instructions. Quantitative analysis of protein
expression was performed by using ImageJ software. Levels of IL-27
were determined by ELISA (eBioscience, San Diego, CA).
Statistical Analysis
Levels of significance for comparison between samples were deter-
mined by the Student’s t test. P values minor to .05 were considered
statistically significant.
Results
IRF-8 Host Deficiency Supports Tumor Growth and
Metastatic Potential of Melanoma
To investigate the role of IRF-8 in melanoma growth control, we
transplanted B16-F10 melanoma cells into IRF-8−/− and WT mice. As
shown in Figure 1A, melanoma grew significantly faster in IRF-8−/−
with respect to WT hosts. These observations paralleled with a
decreased survival time of tumor-bearing IRF-8−/− mice (16.8 ±
4.2 days; Figure 1B) compared to that observed in theWT counterparts
(30.6 ± 8.9 days, Figure 1B). Because B16-F10 cells are also endowed
with the ability to metastasize lung tissue when injected intravenously
into mice [19], we asked whether IRF-8 host deficiency could affect
melanoma cell metastasization. Remarkably, we found a large amount
of metastatic foci in lungs of IRF-8−/− mice with respect to the WT
counterparts as early as 5 days after injection of B16 cells (Figure 1C ).
These results indicate that IRF-8 deficiency promotes both melanoma
growth and metastatic process.
Impaired Immune Cell Infiltration in
Melanoma-bearing IRF-8−/− Mice
We asked whether the inability to control melanoma growth in
IRF-8−/− mice could reflect a defect in immune cell infiltration within
the tumor burden. Staining of tumor tissue sections with H&E
revealed the presence of little dense spots corresponding to leukocyte
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nuclei in melanoma from IRF-8−/−mice (IRF-8–melanoma) with respect
to that from WT animals (WT-melanoma; Figure 2A, red arrows). Of
note, a consistent number of blood vessels indicative of a major vas-
cularization was observed in IRF-8–melanoma sections compared to
WT ones (Figure 2A, yellow arrows). In addition, significantly higher
expression of the angiogenic markers vascular endothelial growth factor
A (VEGF-A), VEGF-B, and VEGF-R2 was found in IRF-8–melanoma,
with respect to WT-melanoma (Figure W2). Flow cytometry analysis of
tumor infiltrates at day 19 post-implantation (p.i.) evidenced a 3.5-fold
lower percentage of CD45+ infiltrating leukocytes in IRF-8–melanoma
compared toWT-melanoma (Figure 2B; P < .001). Furthermore, CLSM
of leukocyte populations revealed little infiltration of DCs and none
of pDCs in IRF-8–melanoma sections, with respect to the WT counter-
parts (Figure 2C ). Notably, the few DCs detected in IRF-8–melanoma
displayed an immature phenotype, revealed by lack of MHC-II
co-expression (Figure 2C ). CD4+ and CD8+ T cells were also barely
detectable in IRF-8–melanoma, while these cells were present in WT-
melanoma (Figure 2C ).
Because IRF-8−/− and WT mice display different tumor growth
kinetics, we addressed whether the extent of immune cell infiltration in
the two strains was associatedwith the tumor burden. Thus, we explanted
melanoma from tumor-bearing IRF-8−/− andWT at three stages of pro-
gression, when tumor size was 10 to 12 mm (early), 20 mm (medium),
or 28 mm (late). At early and medium stages, CD4+ T lymphocytes
were present at comparable levels, whereas CD8+ T cells were slightly
decreased in IRF-8–melanoma with respect to the WT counterparts
(Figure 3A). At late stages of tumor progression, the percentages of
bothCD4+ andCD8+T cells dropped dramatically in IRF-8–melanoma,
whereas they remained constantly present in WT-melanoma (Fig-
ure 3A). Moreover, few CD11c+ DCs infiltrated IRF-8–melanoma
ever since early stages, whereas these cells were found at all stages in
WT-melanoma bulks (Figure 3B). As expected, pDCs (CD11clowB220+)
were almost completely absent in IRF-8–melanoma, being IRF-8−/−
mice devoid of this DC subset (Figure 3C ) [8]. In contrast, pDCs were
detected in WT-melanoma at all stages of tumor progression (Fig-
ure 3C ). Tumor-infiltrating DCs from WT host, but not those from
IRF-8−/− animals, displayed a mature phenotype, shown by expression
of co-stimulatory molecules at the three stages of tumor progression
(Figure 3D). In contrast to what was observed with effector immune
cells, we found much larger numbers of infiltrating MDSCs within
IRF-8–melanoma with respect to WT-melanoma (Figure 4A). Higher
frequencies of MDSCs were also observed in the spleens of melanoma-
bearing IRF-8−/− with respect to WT mice, thus supporting a systemic
suppressive environment in these animals (Figure 4B ). Tregs were
found slightly decreased in melanoma-bearing IRF-8−/−mice compared
to the WT counterparts, both in tumor bulk and spleen (Figure W3).
To evaluate whether the suppressive immune compartment in IRF-8−/−
mice resulted in impaired antitumor response, we transplanted IRF-8−/−
Figure 1. Melanoma progression and metastasis development are highly increased in IRF-8−/− mice. (A) WT and IRF-8−/− mice were
injected s.c. with 0.8 × 106 B16-F10 melanoma cells and tumor size was measured. Data represent the mean tumor diameter ± SD. One
representative experiment of seven is shown. (B) Kaplan-Meyer plot representing percent of surviving mice. Surviving mice after 40 days
(all with tumor) were humanely killed. Histograms depict mean day of death (n = 6–10 mice) ± SD. (C) WT and IRF-8−/− mice were
injected intravenously with B16-F10 cells (1.5 × 106) and sacrificed 5 days later. (Left) Photograph of representative isolated lungs show-
ing metastatic foci (indicated by black arrows). (Right) Counts of lung metastatic foci. Histograms represent the mean number of metas-
tatic foci per lung (n = 10 mice) ± SD. One representative experiment of two is shown. *P < .05, **P < .01, ***P < .001.
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and WT mice with B16.OVA cells and analyzed the response of
CD45+ tumor-infiltrating leukocytes and spleen cells to OVA recall
in vitro. Strikingly, no proliferative response was observed with either
tumor-infiltrating CD45+ (Figure 4C ) or spleen cells (Figure 4D) from
IRF-8−/− mice to OVA stimulation. In contrast, WT immune cells
from both tumor and spleen exhibited significant proliferation in
response to OVA (Figure 4, C and D). Thus, IRF-8 host deficiency
determines defective tumor infiltration of T lymphocytes and mature
DCs but high frequencies of MDSCs in melanoma-bearing mice that
result in a defective antitumor response, thus suggesting a role for
these immune cells in controlling melanoma growth.
Establishment of a Chemokine/Chemokine Receptor Pattern
Supporting Tumor Growth in IRF-8–melanoma
Next, we investigated the intratumoral expression by resident and
infiltrating cells of selected chemokines and chemokine receptors
involved in immune cell trafficking, tumor angiogenesis, and metas-
tasis [20–22]. To this end, we sorted CD45+ cells, representative of
the whole infiltrating leukocyte population and CD45− cells, represen-
tative of the bulk of melanoma cells, and stromal resident cells from
IRF-8–melanoma andWT-melanoma.WT-melanoma showed elevated
levels of CCL19 and CCL21 in the CD45− fraction and of their receptor
CCR7 in the CD45+ fraction (Figure 5). In contrast, this axis, known
to recruit DCs and T cells [22], was completely inhibited in IRF-8–
melanoma (Figure 5). Furthermore, the DCs and T cell–attracting
chemokines CCL20, CCL5, CCL27, and CXCL10 were highly
expressed in both CD45− and CD45+ fractions of WT-melanoma,
while they were significantly suppressed in IRF-8–melanoma (Figure 5)
[23–25]. Of note, CCR5, the receptor for CCL5 known to be associ-
ated with CD8+ T cell cytotoxicity in response to antigen presentation
by DCs [26], was significantly more expressed in the CD45+ fraction of
WT-melanoma with respect to the IRF-8 counterpart (Figure 5). With
Figure 2. Defective leukocyte infiltration in melanoma-bearing IRF-8−/−mice. (A) H&E staining of frozenmelanoma sections from IRF-8−/−
andWTmice at early stage (12-mmmean diameter). Yellow arrows depict blood vessels; red arrows indicate immune infiltrates. (B) FACS
analysis of total infiltrating CD45+ leukocytes. Scatter plots indicate mean percent values of each experiment ± SD. ***P < .001.
(C) CLSM analysis of immune infiltrates in IRF-8–melanoma and WT-melanoma sections. DCs are represented by co-localization (yellow)
of CD11c and MHC-II expression; pDCs (white arrows) are depicted by mPDCA1 expression; CD4 and CD8 T cells are shown by co-
expression of CD3 and CD4 or CD8 markers, respectively (white arrows). Inserts represent high magnification portions of the fields dis-
played. Bars correspond to 100 μm. One representative experiment of two is presented.
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regard to chemokine and chemokine receptors involved in metastasis
and angiogenesis, we found CCR10, which promotes escape from host
immunosurveillance and tumor growth [27,28], expressed at high levels
selectively in the CD45− fraction of IRF-8–melanoma (Figure 5). More-
over, the angiostatic axis CXCL10/CXCR3 [29,30] was significantly in-
hibited in IRF-8–melanoma but highly activated in WT-melanoma
(Figure 5). Conversely, the angiogenic CXCL1 and CX3CL1 chemo-
kines [31] were highly expressed in the CD45− fraction of IRF-8–
melanoma (Figure 5). Together, these data suggest a close correlation
between host IRF-8 expression and a pattern of chemokines/chemokine
receptors that control immune cell infiltration and tumor progression.
IRF-8 Intratumoral Expression Is Suppressed in
IRF-8–melanoma and in Human Metastatic Melanoma
As IRF-8 acts as a tumor suppressor gene in different types of
tumors, we asked whether IRF-8 host deficiency could also influence
the intrinsic expression of IRF-8 in melanoma. To this end, we ana-
lyzed the intratumoral expression of this transcription factor in IRF-
8–melanoma and WT-melanoma at early, medium, and late stages of
tumor progression. Strikingly, no IRF-8 expression, either mRNA (Fig-
ure 6A) or protein (Figure 6B), was observed in IRF-8–melanoma at
the three stages of growth analyzed. In contrast, WT-melanoma dis-
played high IRF-8 expression at early stage, progressively decreasing
at medium to late stages, indicating an inverse correlation between
IRF-8 expression and melanoma progression in immunocompetent
mice (Figure 6, A and B). Importantly, B16-F10 cells expressed basal
levels of IRF-8 before injection, meaning that this factor is upregulated
whenmelanoma cells are transplanted intoWTmice but not into IRF-8−/−
hosts (Figure 6A). We verified IRF-8 expression in sorted CD45+ cells
and CD45− cells. Remarkably, IRF-8 expression was strongly sup-
pressed in the CD45− fraction of IRF-8–melanoma, whereas substantial
mRNA levels were observed in the same fraction of WT-melanoma
(Figure 6C ). As expected, no IRF-8 mRNA expression was found
Figure 3. T lymphocytes and DC trafficking is impaired in IRF-8–melanoma lesions during tumor progression. Melanoma lesions from
WT and IRF-8−/− mice were excised at various stages of growth. (A) FACS analysis of infiltrating CD4+ and CD8+ T lymphocytes gated
on total leukocytes (CD45+) as CD11c−CD4+ (R1 region) and CD11c−CD8+ (R2 region) T cells, respectively. (B) Representative analysis
of infiltrating DCs. R3 region represents CD11c+MHC-II+DC gated on CD45+ cells. (C) Representative analysis of infiltrating pDCs. R4
region represents CD11clowB220+ pDC gated on CD45+cells. Histograms below each panel depict mean percentage values of the
various infiltrating immune cell populations among total CD45+ cells in each group (n = 18 mice) ± SD. (D) Phenotype of DCs. Data
represent the percentage of CD45+CD11c+MHC-II+ DC expressing the indicated co-stimulatory molecules (mean values ± SD). One rep-
resentative experiment of three is shown.
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in theCD45+ fraction from IRF-8–melanoma, whereas it was detected at
very high levels in the same fraction from WT-melanoma (Figure 6C ).
To further determine whether down-regulation of IRF-8 expression
in B16 melanoma correlates with tumor growth and metastasis, we
analyzed the expression levels of IRF-8 in the non-metastatic B16-F0
melanoma cell line [32] compared to that in metastatic B16-F10 cells.
Consistently, B16-F0 cells exhibited significantly higher expression of
IRF-8 with respect to B16-F10 cells (Figure 6D). We asked whether
also in human melanoma cells with diverse grade of malignancy IRF-8
was differentially expressed. To this end, we analyzed IRF-8 mRNA
levels in Colo-38 and M14, originated by primary tumors [33], and
Alo-39, PES-41, PES-43, and PES-47, generated frommetastatic lesions
[16]. Of interest, the metastatic melanoma cell lines exhibited signifi-
cantly lower expression of IRF-8 with respect to the primary melanomas
(P < .05, Figure 6E ). Together, these observations strongly suggest a
strict correlation between intrinsic IRF-8 expression and the metastatic
phenotype of melanoma cells.
Induction of IRF-8 Expression in Melanoma Cells Reactivates
Immune Cell Infiltration and Stimulates Tumor Regression
We investigated whether the induction of IRF-8 into IRF-8–melanoma
could influence chemokine/chemokine receptor profiles, immune cell
infiltration, and tumor progression. To this end, we took advantage of
5-Aza-dC, a DNA methyltransferase inhibitor known to upregulate
IRF-8 expression in malignant cells by epigenetic mechanisms [34].
A single injection of 5-Aza-dC in tumor-bearing IRF-8−/−mice induced
IRF-8 expression in cancer cells as early as 24 hours p.i. (Figure 7A).
5-Aza-dC–induced IRF-8 expression was associated to demethylation
of a CpG island inside the IRF-8 promoter (Figures 7B and W1). In
contrast, IRF-8 expression in WT-melanoma was not affected by treat-
ment with 5-Aza-dC in accordance with the unmethylated status of
melanoma DNA in both 5-Aza-dC–treated and untreated WT mice
(Figure W4). We then investigated whether 5-Aza-dC could influence
tumor infiltration in IRF-8−/− mice. Noteworthy, IRF-8–melanoma
from 5-Aza-dC–treated mice displayed large infiltration of T lympho-
cytes, CD4+ and CD8+ (Figure 7C ), and DCs (Figure 7D). Moreover,
following 5-Aza-dC treatment, the axes CCL21/CCR7 and CCL5/
CCR5 were fully reactivated in IRF-8–melanoma (Figure 7E ). Like-
wise, the expression of CCL20, CCL27, and CXCL10 was strongly
upregulated in melanoma of these mice (Figure 7E ). In addition, 5-Aza-
dC induced up-regulation of the angiostatic axis CXCL10/CXCR3 in
the CD45+ fraction and down-regulation of the angiogenic chemokine
CXCL1 and of CCR10 in the CD45− fraction (Figure 7E ). Of note,
5-Aza-dC promoted a significant expression of CCR10 selectively in
Figure 4. Increased frequency of MDSC and impaired T cell response in tumor and spleen of melanoma-bearing IRF-8−/− mice. (A, B)
Melanoma-bearing IRF-8−/− and WT mice were sacrificed at early tumor stage (12-mm mean diameter). FACS analysis of MDSCs was
performed in tumor bulks (A) and spleens (B). Left-side dot plots show cell population CD45+ gated; right-side plots show the population
gated as indicated by the arrow. Values depicted refer to percent of positive cells over total CD45+ leukocytes. One representative
experiment of three is shown. (C, D) IRF-8−/− and WT mice transplanted with B16.OVA tumors were sacrificed after 17 days and tumors
and spleens were harvested. (C) CD45+ tumor–infiltrating leukocytes were cultured for 4 days with 1 μM SIINFEKL OVA peptide, 0.2 mg/ml
OVA protein, or medium alone. Proliferative response was measured by pulsing with 3H-thimydine for the last 16 hours of culture. Data are
expressed as mean cpm ± SD of culture triplicates. (D) Proliferative response of spleen cells after incubation with graded amounts of OVA
protein. 3H-thimydine incorporation wasmeasured on the fourth day of culture. Data are expressed asmean cpm± SD of culture triplicates.
One representative of two is shown. *P < .05; **P < .01 versus unstimulated.
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the CD45+ fraction of IRF-8–melanoma, in accordance with high
levels of its ligand CCL27, thus suggesting the activation of this
T cell inflammation axis following drug treatment [35] (Figure 7E ).
All these changes correlated with a significant tumor regression in
5-Aza-dC–injected IRF-8−/− mice (Figure 7F). Forty-eight hours after
5-Aza-dC administration, melanoma resumed its growth propensity,
which could then again be blocked by a new 5-Aza-dC injection
(Figure 7F ). Overall, these observations indicate a strict correlation
between IRF-8 expression in melanoma cells and the establishment
of appropriate chemokines and chemokine receptor profiles at the tumor
site that control immune infiltration and tumor growth.
Immune Factors Secreted by Splenocytes of Melanoma-bearing
Mice Affect IRF-8 Expression in B16-F10 Cells
To investigate the interplay between cancer and immune cells, we
assessed whether IRF-8 expression in melanoma cells could be directly
modulated by the release of soluble mediators from the host immune
system. Thus, we co-cultured splenocytes from melanoma-bearing
IRF-8−/− or WT mice (day 19) in transwell plates with B16-F10
melanoma cells and analyzed mRNA IRF-8 expression in B16 cells
after 24 hours. As shown in Figure 8A, IRF-8 expression in B16 cells
was significantly upregulated by splenocytes from tumor-bearing
WT mice with respect to B16 cultured in medium alone. In contrast,
soluble factors released from IRF-8−/− splenocytes failed to upregulate
IRF-8 expression in B16 melanoma cells (Figure 8A ). Of interest,
IRF-8 expression was not induced when B16 cells were cultured with
splenocytes from naïve mice, either WT or IRF8−/−, indicating that the
immune cell–secreted factors were induced in response to melanoma
implant in mice (Figure 8A). To seek for candidate soluble mediators
responsible for IRF-8 up-regulation, we measured an array of cytokines
and growth factors in supernatants from splenocytes/B16 cell co-cultures
(Figure W5). Among the 96 soluble factors tested, we found three
cytokines differentially expressed selectively in splenocytes from tumor-
bearing WT mice, with respect to tumor-bearing IRF-8−/−, naïve WT,
and naïve IRF-8−/− mice (Figure W6). These factors were IL-3, IL-6,
and IL-10 (Figure 8B). Specifically, the protein levels of IL-3 and IL-6
were up-modulated, whereas IL-10 was down-modulated selectively in
co-cultures containing splenocytes of tumor-bearing WT mice with
respect to the other conditions (Figure 8B). Because IL-27 was shown
to regulate IRF-8 expression in B16 melanoma cells [36], we also tested
the levels of this cytokine in the co-cultures and found higher levels in
supernatants from splenocytes of tumor-bearing WT mice with respect
to the IRF-8−/− counterpart (Figure 8C ). We then examined the ability
of IL-3, IL-6, IL-10, and IL-27 to directly modulate IRF-8 expression
in B16 melanoma and found that only IL-27 was able alone to induce
IRF-8 in B16 cells (Figure 8D).Of note, a synergistic effect was observed
when IL-27 was combined with IL-6 (Figure 8D). Addition of IL-10 did
Figure 5. Altered chemokine and chemokine receptor expression in IRF-8–melanoma lesions.Melanomawas excised fromWTand IRF-8−/−
mice (n = 6) at medium stage (20-mm mean diameter); cell suspensions were sorted into CD45+ and CD45− cell fractions and RNA was
purified. qRT-PCR for the indicated chemokines or chemokine receptors was carried out. Histograms represent mean mRNA expression
normalized to β-actin in each sample run in triplicate (mean values ± SD). One representative experiment of three is shown. *P < .05,
**P < .01, ***P < .001.
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not significantly inhibit IL-27/IL-6 combined action and IL-3 did not
affect IRF-8 expression (Figure 8D). To establish a correlation between
intratumoral IRF-8 expression and IL-27 and IL-6 in vivo, we analyzed
the expression of the two cytokines in theCD45+ andCD45− fractions of
IRF-8–melanoma andWT-melanoma. Remarkably, both cytokines were
significantly more expressed in the CD45+ fraction of WT-melanoma
than in the IRF-8−/− counterpart (Figure 8E ). Together, these data
demonstrate that immune cells are endowed with the ability to control
intratumoral IRF-8 expression through the secretion of soluble media-
tors, among which IL-27 and IL-6, and imply IRF-8 as a potential
determinant for the cross talk between immune cells and melanoma.
Discussion
In this study, we report the dual role of IRF-8 as a crucial immune
regulator and as a tumor suppressor factor regulating melanoma pro-
gression and metastasis development. IRF-8 is a major determinant of
myeloid cell development and function [37,38]. This has been clearly
demonstrated in IRF-8−/−mice, which display an altered hematopoiesis,
with impairedmacrophage andDC compartments [11]. Our laboratory
has shown that IRF-8−/−mice are selectively devoid of pDCs and exhibit
reduced frequencies and function of CD8α+ DCs, which are critical for
the induction of protective T cell immunity againstmany pathogens and
tumors [8–10]. Here, we report that the uncontrolled melanoma
growth and the high rate of metastases in IRF-8−/− mice strongly corre-
late with the severely defective immunosurveillance in these mice due to
the effects of IRF-8 deficiency on the immune system. This is indicated
by our observations that IRF-8−/−mice display poor homing of DCs and
T cells at the tumor site, whereas they show large numbers ofMDSCs in
both tumor tissue and spleen. Increased numbers of MDSCs in spleen
and tumor tissue have been described in various murine tumor models
[39]. MDSCs are known to suppress the infiltration and activities of
T cells at the tumor site and to inhibit DCmaturation, thus hampering
the onset of effector antitumor responses [40,41]. Accordingly, the few
DCs infiltrating IRF-8–melanoma exhibited an immature phenotype
and, as expected, lacked totally the pDC component. As a result of this
immunosuppressive environment, T cell–mediated antitumor immune
responses were completely abrogated in IRF-8−/−mice, both at the tumor
Figure 6. IRF-8 expression is inhibited in IRF-8–melanoma and human metastatic melanoma. (A) IRF-8 mRNA expression in melanoma
bulk from WT and IRF-8−/− mice at various stages of growth and in B16-F10 cells before transplantation. Histograms represent mean
expression values normalized to β-actin in each group (18 mice) ± SD. (B) IRF-8 protein expression in melanoma lysates from WT and
IRF-8−/− hosts. β-Tubulin was used as normalization control for IRF-8 expression (E, early; M, medium; L, late stage of tumor growth).
IFN-γ–treated B16 cells were used as positive control. One representative experiment of two is shown. (C) IRF-8 mRNA expression in
sorted CD45+ and CD45− fractions from melanoma-bearing mice at medium stage (20-mm mean diameter). Histograms represent
mean mRNA expression normalized to β-actin in each sample run in triplicate (± SD). One representative experiment of three is shown.
(D) Expression levels of IRF-8 mRNA in non-metastatic (B16-F0, n = 18) or metastatic (B16-F10, n = 18) murine melanoma cells. Bars in
the plot represent mean values of IRF-8 expression normalized to β-actin in the indicated group. (E) Expression levels of IRF-8 mRNA in
the indicated human primary and metastatic melanoma cells. Histograms represent mean values of IRF-8 mRNA expression normalized
to β-actin. *P < .05; ***P < .001.
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site and at systemic level. In keeping with this, at late stage of tumor
development, IRF-8–melanoma contained very few infiltrating CD4+
and CD8+ T cells, crucial effectors of the antitumor immune response
against melanoma [42]. On the contrary, WT-melanoma showed a con-
siderable infiltration of T cells and mature DCs, including a significant
fraction of pDCs, which associated with induced T cell response. Cor-
relation between the presence of intratumoral mature DCs and favorable
clinical prognosis has been established for a variety of human solid tumors,
including melanoma [43,44]. Furthermore, pDC recruitment in mela-
noma lesions has been reported to be an important correlate for the
clinical response triggered by imiquimod, confirming a crucial role
for these cells in the antitumor response against melanoma [45].
Figure 7. Induction of intratumoral IRF-8 expression by 5-Aza-dC reactivates immune cell infiltration and leads to melanoma regression in
IRF-8−/− hosts. Melanoma-bearing IRF-8−/− mice (n = 8) were injected i.p. with 5-Aza-dC or PBS at 17 days after tumor implant. (A)
Western blot analysis of intratumoral IRF-8 expression (24 hours p.i.) and of IFN-γ–treated B16 (positive control). (B) DNA methylation
assay specific for IRF-8 promoter region in IRF-8–melanoma at the indicated experimental conditions (24 h p.i.). M, methylation primers; U,
unmethylation primers. (C) FACS analysis of infiltrating CD4+ and CD8+ T cells. Numbers in plots represent the percentage of CD4+ or CD8+
T cells among CD45+-gated leukocytes. (D) FACS analysis of DCs. Numbers in dot plots represent the percentage of CD45+CD11c+ cells
in tumor bulks. (E) Sorted CD45+ and CD45− fractions from melanoma explants were subjected to qRT-PCR analysis for the indicated
chemokine or chemokine receptors. Histograms represent the relative mRNA amount normalized to β-actin in samples run in triplicate
(mean values ± SD). *P < .05, ***P < .001. (F) Mean tumor diameter of mice treated with 5-Aza-dC or PBS (n = 5–8). One representative
experiment of three is shown.
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At the tumor site, a tight cross talk between various types of cells
occurs, affecting angiogenesis, cancer metastatic potential, and intra-
tumoral immune trafficking through a complex network of cyto-
kines, chemokines, and growth factors [5]. In this scenario, cancer
cells modulate the expression of chemokines and chemokine recep-
tors favoring or inhibiting the homing of immune cells that dictate
the course of tumor progression [31]. Our data clearly reveal a close
correlation between the extent of tumor infiltration and the chemo-
kine expression profiles in IRF-8–melanoma. Indeed, the impaired
expression of the chemokine receptor CCR7 and its two ligands,
CCL19 and CCL21, driving the recruitment of mature DCs and
CD8+ T cells [46], strongly correlate both with the scarce frequency
Figure 8. IRF-8 expression in B16 melanoma cells is modulated by immune cell–derived soluble factors. (A) Spleen cells of melanoma-
bearing or naïveWT and IRF-8−/−mice (n=6)were co-cultured with B16 cells in a 0.4-μmpore size transwell culture system. After 24 hours,
B16 cells were collected, total RNA was purified, and qRT-PCR for IRF-8 mRNA was performed. Histograms represent the mean values of
IRF-8 mRNA expression of triplicate samples normalized to β-actin ± SD. Spl, spleen cells; M, medium alone. One representative experi-
ment of two is shown. (B) Cytokines from supernatants of spleen cell–B16 melanoma co-cultures, as in A, were measured using a com-
mercial protein array and quantified using ImageJ software. Values are expressed in arbitrary units. (C) IL-27 release in the co-cultures, as
measured by ELISA. (D) IRF-8 mRNA expression in B16 melanoma cells after 24 hours culture with the indicated cytokines. Histograms
represent the mean values of IRF-8 mRNA expression of triplicate samples normalized to β-actin ± SD. One representative experiment
of two is shown. (E) IL-27 p28 and IL-6 mRNA expression in sorted CD45+ and CD45− fractions from melanoma-bearing mice at medium
stage (20-mm mean diameter). Histograms represent mean mRNA expression normalized to β-actin in each sample run in triplicate (mean
values ± SD). One representative experiment of three is shown. *P < .05, ***P < .001.
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of these cells and with the immature phenotype of the few available
DCs found in IRF-8–melanoma. Moreover, the absence of infil-
trating pDCs in IRF-8–melanoma correlates with minimal levels of
intratumoral CCL20, shown to participate to pDC recruitment from
the blood to the tumor in melanoma patients [24], and of CCR5/
CCL5, driving antitumor immunity through the activation of DCs
and CD8+ T cells [25]. Noteworthy, these expression profiles were
completely reversed in WT-melanoma, suggesting a potential key
role of IRF-8–mediated DC activity in the induction of melanoma
intratumoral immunity. The expression pattern of chemokine and
chemokine receptors in IRF-8–melanoma is also distinctive of a tumor
microenvironment favoring angiogenesis and metastasis development
and correlates with increased vascularization and expression of angio-
genic factors in these tumors. Indeed, the inhibition of the angiostatic
axis CXCL10/CXCR3, the high levels of the angiogenic CXCL1 and
CX3CL1, and the activation of theCCL27/CCR10 axis indicate amilieu
supporting neoplastic cell growth, metastatic process, and immune
escape [30,31,47–49].
Remarkably, IRF-8 host deficiency resulted in the inhibition of
IRF-8 expression in the transplanted B16 melanoma. Early investiga-
tions revealed that IRF-8 deficiency is associated with the development
of a CML-like syndrome in mice as well as with the expression of BCR-
ABL in CML patients with poor prognosis [12,50]. In addition, recent
reports have identified IRF-8 as a crucial determinant in solid tumor
cell biology and defined this transcription factor as a tumor suppressor
gene [7,14,51,52]. The suppression of IRF-8 function was also found
to correlate with enhanced metastatic potential of cancer cells in a
mouse model of mammary carcinoma [13,15]. Accordingly, we found
that melanoma transplanted in immunocompetent mice exhibits high
IRF-8 expression at early stage of development, progressively declining
with tumor growth, indicating that repression of this transcription
factor is a hallmark of melanoma malignant phenotype. This assump-
tion is further sustained by our observation that metastatic B16-F10
melanoma expresses lower levels of IRF-8 than non-metastatic parental
B16-F0 cells and that in humanmelanoma cell lines IRF-8 expression is
substantially reduced in metastatic with respect to primary melanoma
cells. In this regard, silencing of IRF-8 by DNA methylation or other
epigenetic mechanisms has been associated with the malignant pheno-
type of many hematological and solid cancer cells [34,52].
The observation that IRF-8 expression in B16 melanoma cells is
upregulated following transplantation into WT but not IRF-8−/−
mice supports the concept that host IRF-8 deficiency abrogates the
natural mechanisms of immunosurveillance that normally occur in
immunocompetent animals. Of interest, treatment of melanoma-
bearing IRF-8−/− mice with the demethylating agent 5-Aza-dC, which
induced IRF-8 expression in cancer cells by epigenetic mechanisms,
radically reversed the chemokine expression pattern, re-established
intratumoral trafficking of DCs and T cells, and led to melanoma
growth arrest. Although we cannot rule out the possibility that other
factors, especially tumor suppressor genes, may be induced by 5-Aza-
dC, our observations suggest a close correlation between intratumoral
IRF-8 expression, immune infiltration, and melanoma growth control.
Furthermore, these findings indicate that IRF-8 may function as a
critical determinant in the cross talk between melanoma and infiltrat-
ing cells at the tumor site. In this context, the immune system may
release signals that activate or repress IRF-8 in cancer cells that in turn
shape melanoma phenotype and affect host immunosurveillance.
Indeed, transwell co-culture experiments showed that only immune
cells from melanoma-bearing WT mice, but not those from IRF-8−/−
animals, released soluble factors capable of inducing IRF-8 expression
in B16 cells.
Among the factors responsible for immune cell–cancer cross talk,
we identified IL-27 as a candidate cytokine expressed at higher levels
in tumor-bearing WTmice and able to induce alone IRF-8 expression
in melanoma cells. IL-6, also expressed by WT immune cells, was able
to synergize with IL-27 to upregulate intratumoral IRF-8. Therefore,
the observation that both IL-27 and IL-6 were significantly up-regulated
in the CD45+ fraction of WT-melanoma, with respect to IRF-8–
melanoma, suggest that these cytokines may play a coordinate role in
controlling intratumoral IRF-8 expression in vivo. Although tumor-
released IL-6 has been reported to act as a pro-tumorigenic factor in
advanced melanoma, its role in host antitumor response is less clear
[53]. Instead, IL-27 has been shown to exert anti-proliferative activ-
ity on B16 melanoma through a mechanism involving IRF-1 and
IRF-8 up-regulation [36]. Of interest, IRF-8–deficient macrophages
were shown to be highly defective in the production of IL-27 [54].
Our results are in line with these reports and suggest the existence of a
mutual regulatory pathway linking IRF-8 and IL-27. Hence, IRF-8−/−
host deficiency may impair IL-27 production by innate immune cells
resulting in failure to upregulate intratumoral IRF-8 inmelanoma cancer
cells, which in turn acquire a more aggressive phenotype escaping
immune surveillance. Whether and which other factors besides IL-27
are involved in IRF-8–driven immunosurveillance against melanoma
will need further investigations. Nevertheless, our results unravel a
clinically relevant role of IRF-8 in bridging cancer and immune cross
talk in the control of melanoma progression and metastatic process
within the tumor microenvironment, thus opening new perspectives
for the design of innovative therapies for melanoma patients.
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Figure W1. Analysis of a CpG island inside the promoter region of the mouse IRF-8 gene. (A) The promoter region of IRF-8 gene (MGI
Identifier No. 96395) was analyzed from 2000 bp upstream the transcription initiation site (+1). The analyzed CpG island, detected by
Methyl Primer Express software, is located at positions 1834 to 1544 bp before the initiation of transcription. The entire sequence,
comprising the 2000-bp promoter region of IRF-8 gene and IRF-8 gene itself, is available online in the Nucleotide database of NCBI
web site (http://www.ncbi.nlm.nih.gov/sites/entrez; Contig Sequence No. NT_078575.6). Black line, IRF-8 promoter sequence; gray line,
IRF-8 gene sequence; white box, CpG island. (B) Detail of the analyzed CpG island. Horizontal black arrows depict primers used for
detection of methylated or unmethylated status of the CpG island by DNA methylation–specific PCR. Discontinued line shows the am-
plicon obtained by the assay for both methylation and unmethylation primers. Vertical black thin lines show CpG sequences detected
inside the analyzed CpG island.
Table W1. Murine and Human Primers Used for qRT-PCR.
Gene Forward and Reverse Primers (5′→3′) NCBI Accession Number Amplicon Size (Base Pairs)
IRF-8 TGATCGAACAGATCGACAGC NM_008320.3 187
GCTGGTTCAGCTTTGTCTCC
CCL5 ATATGGCTCGGACACCACTC NM_013653.3 123
GTGACAAACACGACTGCAAGA
CCL21 GTGATGGAGGGGGTCAGGA NM_011124.4 109
GGGATGGGACAGCCTAAACT
CCL27 CTGCTGAGGAGGATTGTCCAC NM_011336 69
CACGACAGCCTGGAGGTGA
CXCL1 GCTGGGATTCACCTCAAGAA NM_008176.2 180
TCTCCGTTACTTGGGGACAC
CCR7 ACAGCGGCCTCCAGAAGAACA NM_007719.2 345
TGACGTCATAGGCAATGTTGAGCT
CCR10 GCCAGAGATGGGGACCAAGCC NM_007721.4 143
TGGGTTGGAAGGCCCGACTGA
CCL19 GGCCTGCCTCAGATTATCTGCCAT NM_011888.2 173
GGAAGGCTTTCACGATGTTCC
CX3CL1 ACGAAATGCGAAATCATGTGC NM_009142 120
CTGTGTCGTCTCCAGGACAA
CXCR3 TACCTTGAGGTTAGTGAACGTCA NM_009910 100
CGCTCTCGTTTTCCCCATAATC
CXCL12 GAGCCAACGTCAAGCATCTG NM_013655.3 96
CAATGCACACTTGTCTGTTG
CXCL10 CTCTCGCAAGGACGGTCCGC NM_021274.1 166
TCCGGATTCAGACATCTCTGCTCAT
CCR5 GCCAGAGGAGGTGAGACATCCGT NM_009917.5 163
GGCAGGAGCTGAGCCGCAAT
CCL20 GACAGATGGCCGATGAAGCTT NM_016960.1 108
TCACAGCCCTTTTCACCCAGT
IL-6 GAGGATACCACTCCCAACAGACC NM_031168 141
AAGTGCATCATCGTTGTTCATACA
IL-27 p28 CTGTTGCTGCTACCCTTGCTT NM_145636.1 177
CACTCCTGGCAATCGAGATTC
VEGF-A AAAGGCTTCAGTGTGGTCTGAGAG NM_001025250 184
GGTTGGAACCGGCATCTTTATC
VEGF-B TTAGAGCTCAACCCAGACACCTGTA NM_011697.3 104
CCTGTGAAGCAGGGCCATAA
VEGF-R2 GCCCTGCTGTGGTCTCACTAC NM_010612 114
CAAAGCATTGCCCATTCGAT
β-Actin AGAGGGAAATCGTGCGT NM_007393.3 138
CAATAGTGATGACCTGGC
IRF-8 (human) AGTAGCATGTATCCAGGACTGAT NM_002163.2 196
CACAGCGTAACCTCGTCTTC
GAPDH (human) ATGGGGAAGGTGAAGGTCG NM_002046.3 108
GGGGTCATTGATGGCAACAATA
Figure W2. Expression of angiogenic factors in tumor bulks. Melanoma was excised from WT and IRF-8−/− mice (n = 3) at medium
stage (20-mm mean diameter), and mRNA was extracted. qRT-PCR for the indicated angiogenic markers was performed. Histograms
represent the amount of mRNA expression normalized to β-actin for each experimental condition run in triplicate (mean values ± SD).
One representative experiment of two is shown.
Figure W3. Frequency of Tregs in tumor and spleen of melanoma-
bearing IRF-8−/− mice. Melanoma-bearing IRF-8−/− and WT mice
were sacrificed at early tumor stage (12-mm mean diameter).
FACS analysis of Tregs in tumor bulks (A) and spleens (B). Left-
side dot plots show total live cell population; right-side plots show
the population gated as indicated by the arrow. Values depicted
refer to percent of positive cells over total live cells. One represen-
tative experiment of three is shown.
Figure W4. WT mice (n = 8) were injected s.c. with B16-F10 mela-
noma cells. At day 17 post-injection, mice were injected i.p. with
PBS or 5-Aza-dC. Twenty-four hours later, mice were sacrificed
andmelanomawas excised. (A)Western blot analysis of intratumoral
IRF-8 expression in WT-melanoma lesions. Numbers represent the
size of protein weight markers. One representative experiment of
two is shown. (B) DNAmethylation assay specific for IRF-8 promoter
region inWT-melanoma lesions at the indicated experimental condi-
tions. M, methylation primers; U, unmethylation primers. Numbers
represent length of DNA molecular weight markers.
Figure W5. Differential cytokine release by immune cells from melanoma-bearing or naïve WT versus IRF-8−/− mice. Cytokines from
supernatants of spleen cell–B16 melanoma co-cultures (24 hours) were measured using a protein array kit and quantified using ImageJ
software. (A) Full array of differentially expressed cytokines in spleen cells of melanoma-bearing WT versus IRF-8−/− mice. Orange,
cytokines upregulated in WT cells; blue, cytokines upregulated in IRF-8−/− cells; black, cytokines not differentially expressed. Analysis
of protein expression of WT-upregulated cytokines (B) and of IRF-8–upregulated cytokines (C) in tumor-bearing and naïve mice. Values
are expressed in arbitrary units. One experiment of two is shown.
Figure W5. (continued).
